Myriad Genetic Laboratories

FDA approves lynparza for breast cancer with BRCA gene mutation

15 January 2018 | By Dr Zara Kassam (European Pharmaceutical Review)

The FDA has expanded the approved use of Lynparza to include the treatment of patients with metastatic breast cancer who have a BRCA gene mutation...